



08-20-02

Gp/1636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Micheal L. Gruenberg

Serial No.: 10/071,016

Filed: February 7, 2002

For: **Th1-CELL ADOPTIVE  
IMMUNOTHERAPY**

Art Unit: 1636

Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS  
MAIL"

"Express Mail" Mailing Label Number

EV177690239US

Date of Deposit August 15, 2002

I hereby certify that this paper is being deposited  
with the United States Postal "Express Mail Post  
Office to Addressee" Service under 37 C.F.R.  
§1.10 on the date indicated above and addressed  
to:

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

 8/15/02  
Michael Lough Date

TRANSMITTAL LETTER

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

AUG 22 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is a Preliminary Amendment for filing with the above-referenced application.

( X )      The Commissioner is hereby authorized to charge any fees that may be  
due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with  
this application during its entire pendency to Deposit Account  
No. 50-1213. A duplicate of this sheet is enclosed.


\* \* \*

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE

By:

  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket 24731-504B  
Address all correspondence to:  
HELLER EHRMAN WHITE & McAULIFFE  
4350 La Jolla Village Drive, 7th Floor  
San Diego, CA 92122-1246  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
E-mail: sseidman@HEWM.com



#3/K.T.  
8/22  
Pre/A

Applicant: Micheal L. Gruenberg

Serial No.: 10/071,016

Filed: February 7, 2002

For: **Th1-CELL ADOPTIVE  
IMMUNOTHERAPY**

Art Unit: 1636

Examiner: Unassigned

**CERTIFICATE OF MAILING BY "EXPRESS**

**MAIL"**

"Express Mail" Mailing Label Number

EV177690239US

Date of Deposit August 15, 2002

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to:

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

  
Michael Lough

8/15/02  
Date

**PRELIMINARY AMENDMENT**

**RECEIVED**

Commissioner for Patents  
Washington, D.C. 20231

AUG 22 2002

TECH CENTER 1600/2900

Dear Sir:

Preliminary to examination of the above-captioned patent application, please amend the application as follows:

**IN THE SPECIFICATION:**

Please amend the specification as follows (a marked up copy of the amended specification is attached to this Amendment):

**Please replace the paragraph on page 22, lines 3-28, with the following;**

A<sup>1</sup>  
Tumor cells are known to produce a variety of Th2 cytokines (Chen *et al.* (1994) *International Journal of Cancer* 56:755; Asselin-Paturel *et al.* (1998) *Journal of Cancer* 77:7; Smith *et al.* (1994) *American Journal of Pathology* 145:18; Vowels *et al.* (1994) *Journal of Investigative Dermatology* 103:669; Nitta *et al.* (1994) *Brain Research* 649:122). Tumor infiltrating cells also produce Th2 cytokines (Roussel *et al.* (1996) *Clinical and Experimental Immunology* 105:344). Freshly isolated RCC cells produce IL-10 (Nakagomi *et al.* (1995) *International Journal of Cancer* 63:366; Wang *et al.* (1995) *International Journal of Cancer* 61:780), a Th2 cytokine. IL-10 is a potent inhibitor of tumor cytotoxicity (Nabioullin *et al.* (1994) *Journal of Leukocyte*